For ACTIVATE-T, the Phase III single-arm open-label study in 27 adults with PK deficiency who are regularly transfused, we anticipate top line data in the first quarter of 2021, given the longer follow-up time in this study. If positive, we expect to file for regulatory approval for a broad label in adults with PK deficiency in both the U.S. and EU next year with a potential 2022 commercial launch in both geographies. Moving to the Phase II study of mitapivat and thalassemia, we completed enrollment earlier this year with 20 patients. And in June, we presented updated data on 13 efficacy evaluable patients at the virtual EHA meeting. The data showed that treatment with mitapivat induced a hemoglobin increase of greater than or equal to one gram per deciliter in 12 of 13 evaluable patients during weeks four through 12, including four out of four alpha-thalassemia patients where there have been no new treatment options in decades.